Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Ovarian Neoplasms 4Fallopian Tube Neoplasms 4Endometrial Neoplasms 4Breast Neoplasms 4Uterine Cervical Neoplasms 3Prostatic Neoplasms 3Pancreatic Neoplasms 3Carcinoma, Ovarian Epithelial 3Urinary Bladder Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Lung Neoplasms 2Leiomyosarcoma 2Urethral Neoplasms 1Ureteral Neoplasms 1Stomach Neoplasms 1Solid Tumor 1Small Cell Lung Carcinoma 1Sarcoma 1Recurrence 1Prostate Cancer Metastatic 1Mesothelioma, Malignant 1Mental Retardation, X-Linked, With Or Without Seizures, Arx-Related 1Esophageal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinosarcoma 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Endometrioid 1

Interventions

talazoparib 1rucaparib 1Docetaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × ATM Gene Mutation × rucaparib × Clear all
NCT03442556 2025-06-12

Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency

University of Washington

Phase 2 Terminated
18 enrolled
Genitourinary

ATM Gene Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡